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Adventitious Viral Genomes
in Vaccines but Not in Vaccinees
It is a pleasant change to write about
viruses that might have emerged but haven’t.
In this issue, Hussain and colleagues at the
Centers for Disease Control and Prevention, the
U.S. Department of Agriculture, and Harvard
University report that recipients of measles,
mumps, and rubella (MMR) vaccine show no
evidence of infection by endogenous avian
retroviruses, even though viral genomes and
reverse transcriptase activity have been de-
tected in vaccine preparations. Influenza,
yellow fever, and MMR vaccines are usually
prepared in embryonated eggs or in cultures of
chick embryo fibroblasts (CEF). These fibro-
blasts contain and express endogenous
retroviral genomes (1). In any vaccine, adventi-
tious agents in the cellular substrate may
contaminate the biological product. In live,
attenuated vaccines, such contaminants are not
inactivated, and endogenous retroviruses by
their very nature as Mendelian transmitted
genomes are particularly difficult to eliminate.
Endogenous retrovirus release also has ramifi-
cations for pharmaceutical proteins made in cell
substrates (e.g., monoclonal antibodies) and for
xenotransplantation (2,3).
Some 45 years ago, it was found that
apparently healthy hens could transmit avian
leukosis virus (ALV) vertically in eggs (4); later
it was demonstrated that live virus vaccines
made in CEF were contaminated with infec-
tious ALV (5). However, no increased risk for
cancer was found in yellow fever vaccinees with
the longest presumed exposure to ALV (6).
Nevertheless, vaccine manufacturers were soon
required to use eggs or CEF from leukosis-free
flocks. To screen for ALV infection, a comple-
ment fixation for ALV (COFAL) antigen test
was devised, and through pioneering work in
the 1960s, the existence of endogenous
retroviruses came to light because many ALV-
free birds were COFAL positive (7-9).
As a graduate student at the time, I ob-
served that CEF of COFAL-positive embryos
complemented envelope-defective Rous sarcoma
virus, yielding pseudotype viruses with xenotro-
pic properties. The endogenous virus was
genetically transmitted in chickens but was
infectious for other hosts such as quail and
pheasant. Many copies of partial or complete
ALV genomes were located in chicken DNA (1).
We showed that ALV had colonized the host
germ line of red jungle fowl before domestica-
tion to become chickens but after divergence of
the genus Gallus into distinct species. Even so,
it proved possible in the 1970s to breed white
leghorns free of endogenous ALV genomes; such
chickens are now being introduced by Merck as
preferred substrates for vaccine production.
A second class of endogenous avian
retroviral genome (EAV), discovered in 1985
(10), is present in all breeds of chicken and
cannot be eliminated. EAV can release nonin-
fectious virus particles containing active re-
verse transcriptase; and this is the genome
most commonly found in MMR and other
vaccines (Hussain et al., this issue; 11). The
major retroviral pathogen of meat-strain
chickens is an infectious recombinant between
ALV gag and pol genes and an env gene related
to EAV (12). This virus has not been observed
to infect human cells.
May we assume, therefore, that chicken cell
substrate vaccines are safe? With biological
products, as with crossing the street, there is no
such thing as absolute safety. The paper by
Hussain et al. is reassuring, and I agree with
the authors that no change in current U.S.
policies (or WHO policies, for that matter) is
warranted, and the public should continue to
enjoy the benefit of the vaccine. However, it
may be useful to probe the possibility of interac-
tion between endogenous avian viruses and the
infectious components of MMR. We showed that
vesicular stomatitis virus (VSV) could assemble
its glycoprotein G on avian retrovirus virions
and vice versa (13). Indeed, VSV G protein has
become an envelope of choice for retroviral
vectors developed for gene therapy. By analogy,
the assembly of the hemagglutinin and fusion
glycoproteins of measles or mumps viruses
might confer a human host range on
endogenous ALV or EAV particles. The
possible generation of such pseudotypes or
phenotypically mixed virions in vaccines may
be worthy of investigation.
In addition, with ultrasensitive techniques,
such as polymerase chain reaction (PCR) gene
amplification, we can detect viral genomes and
reverse transcriptase activity more readily in
vaccine preparations. Virtually all vertebrates
studied, including humans, carry endogenous
retroviral genomes as part of their natural154 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
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genetic constitution (1,14). Therefore, almost
any cell substrate for vaccine production (avian,
rodent, or primate) is likely to contain and
express (at low level) endogenous retroviral
genomes.
Vaccine contamination by adventitious
viruses in the cellular substrate has, of course,
occurred before. In one instance, the discovery
of SV40 in rhesus macaque kidney cultures (15)
soon led to the adoption of cynomolgus macaque
and later African green monkey (AGM) kidneys
as the preferred substrate for polio vaccines.
That was, perhaps, a near escape as AGMs are
now known to frequently harbor a strain of
simian immunodeficiency virus (SIV) that
luckily does not appear to infect humans.
Following the potential exposure of millions of
polio vaccinees to SV40, no evidence was found
of increased cancer incidence (16). More re-
cently, it has been reported that SV40 is
present in some human cancers (17). Cases
include pediatric tumors in patients born long
after SV40 was eliminated from polio vaccines.
Ironically, it was the misguided attention of
regulatory groups on hypothetical oncogenic
DNA that led to vaccine contamination by
adventitious oncogenic viruses in the first place.
Fear of oncogenic DNA made tumor cell lines
taboo as cellular substrates for vaccine produc-
tion. Despite all we have learned about
oncogenes and tumor suppressor genes in
multistep progression to cancer, the possible
trace of “oncogenic” DNA in vaccines prepared
in established cell lines remained of greater
concern to regulators than adventitious infec-
tions in primary cells. It is high time to reevalu-
ate the relative risks, so it is heartening that
the Food and Drug Administration held a
workshop last year to begin that process.
Robin A. Weiss
University College London, London, UK
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